Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.59 |
| ▸ | MLNR | O43193 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | CCKAR | P32238 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19100718 | 0.91 | EGFR (0.60) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19337197 | 0.90 | EGFR (0.70) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19100652 | 0.88 | EGFR (0.60) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19337193 | 0.88 | EGFR (0.58) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19100709 | 0.88 | EGFR (0.58) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19100160 | 0.87 | EGFR (0.61) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL20610635 | 0.87 | EGFR (0.61) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19337068 | 0.87 | EGFR (0.56) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19100429 | 0.86 | EGFR (0.60) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19089469 | 0.85 | EGFR (0.54) | EGFRMLNRKDM1AABCB11ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
| EP-3399968-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmatech Limited (KY) | 2018-11-14 | — | — | EP | disclosed |
| WO-2017120429-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmasciences, Inc. (US) | 2017-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | EGFR 1/4885MLNR 2212/4885KDM1A 1965/4885 |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | EGFR 1/4885MLNR 2212/4885KDM1A 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.